Search research articles
Contact Us
Filters
Showing results (81-90 of 130) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Robert Dreicer, Jorge Garcia, Maha Hussain, et al.
Molecular and Clinical Oncology
|
April 25, 2022
Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer
Earle F Burgess, Chad Livasy, Sally Trufan, et al.
JCO Oncology Practice
|
April 21, 2020
Levine Cancer Institute Approach to Pandemic Care of Patients With Cancer
Derek Raghavan, Edward S Kim, S Jean Chai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
Thomas W Flaig, Catherine M Tangen, Maha H A Hussain, et al.
JCO Precision Oncology
|
December 7, 2023
RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer
Landon C Brown, Jason Zhu, Elizabeth Mauer, et al.
Urologic Oncology
|
October 11, 2019
High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy
Earle F Burgess, Chad Livasy, Sally Trufan, et al.
European Urology Open Science
|
November 21, 2025
Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial
Landon C Brown, Danielle Boselli, James T Symanowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 12, 2004
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer
Glenn Liu, David R Gandara, Primo N Lara, et al.
BJU International
|
August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy
Scott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2025
The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation
Thomas G Knight, Caitlin Hensel, Kris Blackley, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 130) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Robert Dreicer, Jorge Garcia, Maha Hussain, et al.
Molecular and Clinical Oncology
|
April 25, 2022
Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer
Earle F Burgess, Chad Livasy, Sally Trufan, et al.
JCO Oncology Practice
|
April 21, 2020
Levine Cancer Institute Approach to Pandemic Care of Patients With Cancer
Derek Raghavan, Edward S Kim, S Jean Chai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
Thomas W Flaig, Catherine M Tangen, Maha H A Hussain, et al.
JCO Precision Oncology
|
December 7, 2023
RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer
Landon C Brown, Jason Zhu, Elizabeth Mauer, et al.
Urologic Oncology
|
October 11, 2019
High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy
Earle F Burgess, Chad Livasy, Sally Trufan, et al.
European Urology Open Science
|
November 21, 2025
Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial
Landon C Brown, Danielle Boselli, James T Symanowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 12, 2004
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer
Glenn Liu, David R Gandara, Primo N Lara, et al.
BJU International
|
August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy
Scott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2025
The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation
Thomas G Knight, Caitlin Hensel, Kris Blackley, et al.
Page
of 13